Ubsets Name Methylmalonic actoemia mutase dericency Atternate name(s) Methylmalonic action alue to methylmalonic CAC mutase deficiency. Complementation group mut0. Methylmalonic CAC mutase deficiency. Complementation group mut0. Methylmalonic acidemia and homocystinuria Yras Variant name Vitamin B12 metabolic defect with methylmalonic acidemia and homocystinuria yreseen by the end of the first month. How may remain asymptomatic or present much later in life depending on the residual enzyme activity and the metabolic streasors. Symptom onset Eighty parcent of infants become ill during the first work or life and 90% will present by the end of the first month. How may remain asymptomatic or present much later in life depending on the residual enzyme activity and the metabolic streasors. Symptoms Most common signs and symptoms are lethargy failure to thrive, recurrent wonting, dehydration which leads to profound metabolic adidosis, respiratory distress, hypotonia and debase to asymptomatic individuals. Patients do not have to have clinical crises in order to have neurological or other organ compromise. Natural history without treatment Variable depending on the enzyme defect and the patient. Some will die as a neonate, others will survive with deficits and a few others will remain asymptomatic. Natural history with treatment About 60% of patients die within the first year of life and of those that survive, 40% are distinct of howelphant are one soft asymptoms and how proved bichemical values. Renal transplant shave significant proparaties do that patients do not all exels, normalization of the diet and absence of acuse opsical survive, and inverkingent exels.	D'anna Nama	
Complementation group mut0, Methylmalonyl-CoA mutase Complementation group mut0, Methylmalonyl-CoA mutase Complementation group mut0, Methylmalonyl-CoA mutase Variants Presse Classification Variants Variant name Vitamin B12 metabolic defect with methylmalonic acidemia and homocystimuria Yes Variant name Vitamin B12 metabolic defect with methylmalonic acidemia and homocystimuria present by the end of the first month. A few may remain asymptomatic or present much later in life depending on the residual enzyme activity and the metabolic stressors. Mest common signs and symptoms are lethargy, failure to thrive, recurrent womting, dehydration which leads to profound metabolic acidesis, respiratory distress, hypotonia and death if not recognized. Complications of acute episodes can include metabolic stroke, extrapyminal al sign, dystonia and bilateral lucencies of globus palifulus. Survivors may have significant neurological damage. Renal failure may appear during childhood. Clinical spectrum is wide, ranging from fatal neonatal disease to asymptomatic individuals. Patients do not have to have chincic drises in order to have nuclogical or other organ compromise. Variable depending on the enzyme defect and the patient. Some will die as a neonate, others will survive with deficits and a few others will remain asymptomatic. About 60% of patients die within the first year of life and of those that survive, 40% are distinctly developmentally impaired. Age of onset of symptoms can help progneticate - those with later onset then to have. New mateina asymptomatic on therean on the residual explaines asymptomatic. Physical phenotype However, the effect of any type of transplant is limited because the MMA enzyme is in all tissues and there is documentation of neurological organ problems after transplant desplate improved biochemical values. Some patients have significant proporation risk and there is documentation in explaines have significant proporation risk and there is documentation in enterly additing transplant desplate	Disease Name	Methylmalonic acidemia mutase deficiency
Disease Classification Organic Acid Disorder Variants Yes Variant name Vitamin B12 metabolic defect with methylmalonic acidemia and homocystinuria Symptom onset Eighty percent of infants become ill during the first week or life and 90%, will present by the end of the first month. Infants with the less severe mut-may present later than the first month. A few may remain asymptomatic or present much later in life depending on the residual enzyme activity and the metabolic stressors. Symptoms Most common signs and symptoms are lethargy, failure to thrive, recurrent vomiting, dehydration which leads to profound metabolic acidosis: respiratory distress, hypotonia and death if not recognized. Complications of acute episodes can include metabolic strike, extrapyranidal signs, dystonia and biateral lucencies of globus palifieds. Survivors may have significant of an other and profile acidosis: respiratory distress, hypotonia and death if not recognized. Complications of acute episodes can include metabolic astrike, extrapyranidal signs, dystonia and biateral lucencies of globus palifieds. Survivors may have significant semicities in order to have neurological or other organ compromise. Natural history without treatment variable, offers will survive with deficits and a few others will remain asymptomatic have significant properative risk and there is down thave a more being norume. Liver and liver/kidney transplant are one treated mote advest by normalization of the det and abarce of acute episodes of metabolic decompensation. However, the effect of any type of transplants have significant properative risk and there is obsplant so hord affect with relevants made in the cerebrospinal fluid and brain. Physical phenotype Most patients have no obvious and the ransplant so hord affect hydronephrosis and facial dysmophisms. Linkeriance Autosomal recessive He Most patients have no noral splants have a diverse specific and there is specific metiod commendation of the det and abarce of acute periodes of metabolic decompensation. H	.,	Complementation group mut0, Methylmalonyl-CoA mutase
Variant sme Yeš Variant name Vitarim B12 metabolic defect with methylmalonic acidemia and homocystinuria Symptom onset Eighty percent of infants become ill during the first week or life and 90%, will Symptom onset Eighty percent of infants become ill during the first week or life and 90%, will Symptoms Most common signs and symptoms are leftargy, failure to thrive, recurrent vomiting, dehydration which leads to profound metabolic acidosis, respiratory dehydration which leads to profound metabolic acidosis, respiratory distress, hypotonia and death if not recognized. Complicated complicates of globus palitoxis. Survivoes may have significant or leaders in note to have neurological or other organ componise. Natural history without treatment Natural depending on the enzyme defect and the patient. Some will die as a nonate, others will survive with deficits and a few others will remain asymptomatic. Natural history with treatment Abot 60% of patients die within the first year of life and of those that survive, 40% are distinctly developmentally impaired. Age of onset of symptoms can help prognosticat - bokes with later onset that ot have a more benign course. Liver and liver/kidney transplant tare one treatment option. However, liver transplants have significant despite improved biochemical values. Renal transplants have significant despite improved biochemical values. Renal transplants have shown goor deproses with date or live devels. Natural history with treatment Protein restricted diet, OH-Cbl injections, carnitine supp		
Variante name Vitamin B12 metabolic defect with methylmalonic acidemia and homocystinuria Symptom onset Eighty percent of infants become ill during the first week or life and 90% will present by the end of the first month. Infants with the less severe mut-may present later than the first month. A few may remain asymptomatic or present much later in life depending on the residual enzyme activity and the metabolic stressors. Symptoms Most common signs and symptoms are lethargy, failure to thrive, recurrent working, delydration which leads to profound metabolic acidosis. respiratory distress. hypotonia and death if not recognized. Complications of acute episodes can include metabolic stoke, extrapyrandal signs, dystonia and binterail lucencies of globus palitidus. Survivors may have significant sensitive to have clinical crises in order to have neurological or other organ compromise. Natural history without treatment Variable dapanding on the enzyme defact and the patient. Some will die as a neonate, oners will survive with deficits and a few others will remain asymptomica. Natural history with treatment Adov ador dapanding on the enzyme defact and the patient. Some will die as a neonate, oners will survive with deficits and a few others will remain asymptomica. Natural history with treatment Adov ador sponse with later onset tend to have a more being: course. Liver and liver/kindry transplant are one treatment option. Natural history with treatment Adov ador response with drops in methylmalonic acid levels, normalization of the dia ad absence of acute episodes of metabolic decompensation. However, the effect of any type of transplants have significant preoperati		
Symptom onsetEighty percent of infants become ill during the first work of life and 90% will present by the end of the first month. Infants with the less sever mut-may present later than the first month. A fark with yer main asymptomatic or present much later in life depending on the residual enzyme activity and the metabolic stressors.SymptomsMost common signs and symptoms are lethargy, failure to thrive, recurrent vomiting, dehydration which leads to profound metabolic acidosis, respiratory distress, hydronia and death if not recognized. Complications of acute episodes can include metabolic stroke, extraprartidal signs, dystonia and belteral lucencies of globus pallidus. Survivors may have significant neurological damage. Renal failure may appear during childhood. Clinical spectrum is vide, ranging firom fatal neonatal disease to asymptomatic individuals. Patients do not have to have clinical crises in order to have neurological or other oney metal. Survivors will survive with deficits and a few others will remain asymptomatic.Natural history with treatmentVariable depending on the enzyme defect and the patient. Some will die as a neonate, others will survive with deficits and a few others will enzyme adve significant preoprative risk and there is documentation of neurological problems after transplant are one treatment option. However, liver transplants have song/floant preoprative risk and there is documentation and cost is have somy door resonse with drops in methylymalonic acid levels, normalization of the diet and absence of acute episodes of metabolic decompensation. However, the effect of any type of transplant is limited because the MMA enzyme is in all tissues and the transplants do not affect the levels normalization of the diet and absence of acute episodes of metabolic decompensation. However, herefect of any type of transplant i		
present later than the first month. Infaints with the less severe mut-may present later than the first month. A few may remain asymptomatic or present much later in life depending on the residual enzyme activity and the metabolic stressors. Symptoms Most common signs and symptoms are lethargy, failure to thrive, recurrent vomiting, dehydration with leads to profound metabolic actions; respiratory distress, hypotonia and death if not recognized. Complications of acute episodes can include metabolic stroke, extrapyramidal signs, dystonia and bilateral lucencies of globus palidus. Survivors may have significant neurological dramage. Renal failure may appear duing childhood. Clinical spectrum is wide, ranging from fatal neonatal disease to asymptomatic individuals. Patients do not have to have form fatal neonatal disease to asymptomatic. Natural history without treatment About 60% of patients die within the first year of life and of those that survive, 40% are distinctly developmentally impaired. Age of onset of symptoms can help prognosticate – those with later onse tend to have a nore benign course. Liver and liver/kidnetly developmentally impaired. Age of onset of symptoms can help prognosticate ransplant dashesere of acute episodes of metabolic acid levels, normalization of the diet and absence of acute episodes of metabolic acid levels. Normalization of the diet and absence of acute episodes of metabolic acid levels and liver/kidnet yot to decrease gut production s, cantile supplementation and oral arbitotic therapy to decrease gut production of propionate. Special medical foods (formula) deficient in methonine, threonine, value, isocial of dows for manipation dashesere of acute episodes of metabolic docompensation. How wer, liver kidneys, cerebrospinal fluid, drain Natural history with treatment Most costient. Liver, kidneys, cerebros		
 vomiting, dehydrátion which leads to profound metabolic acidosis, respiratory distress, hypotonia and death if not recognized. Complications of acute episodes can include metabolic stroke, extrapyramidal signs, dystonia and bilateral lucencies of globus pallidus. Survivors may have significant neurological damage. Renal failure may appear during childhood. Clinical spectrum is wide, renging from fatal neonatal disease to asymptomatic individuals. Patients do not have to have clinical crises in order to have neurological or other organ compromise. Variable depending on the enzyme defect and the patient. Some will die as a neonate, others will survive with deficits and a few others will earna asymptomatic. Natural history with treatment About 60% of patients die within the first year of life and of those that survive, 40% are distinctly developmentally impaired. Age of onset of symptoms can help prognosticate – those with later onset tend to have a more benigneal to and liver/Kichney transplant are one treatment option. However, liver transplant and envelopmentally impaired. Age of onset of symptoms can help prognosticate – those with later onset tend to have a more benejneal have significant preoperative risk and there is documentation of neurological problems after transplant despite improved biochemical values. Renal transplants have shown good response with drops in methylmatonic acid levels, normalization of the diet and absence of acute episodes of metabolic decompensation. However, the effect of any type of transplant is limited because the MMA enzyme is in all tissues and the transplant do and areal antibiotic therapy to decrease gut production of propionate. Special medical foods (formula) deficient in methionine, threonine, value, isoleucine, odd chain fatty acids and cholesterol. Liver transplant and liver/Kidney transplant. Autosomal facel dysmorphic features. Some patients, in whom there is known consanguinity, have had associated birth defects, congenital heart	Symptom onset	present by the end of the first month. Infants with the less severe <i>mut</i> -may present later than the first month. A few may remain asymptomatic or present much later in life depending on the residual enzyme activity and the metabolic
Natural history without treatment Variable depending on the enzyme defect and the patient. Some will die as a neonate, others will survive with deficits and a few others will remain asymptomatic. Natural history with treatment About 60% of patients die within the first year of life and of those that survive, 40% are distinctly developmentality impaired. Age of onset of symptoms can help prognosticate – those with later onset tend to have a more benign course. Liver and liver/kidney transplant are one treatment option. However, liver transplants have significant preoperative risk and there is documentation of neurological problems after transplant despite improved biochemical values. Renal transplants have significant preopense with drops in methylmalonic acid levels, normalization of the diet and absence of acute episodes of metabolic decompensation. However, the effect of any type of transplant is limited because the MMA enzyme is in all tissues and the transplants do not affect the levels made in the cerebrospinal fluid and brain. Treatment Protein restricted diet, OH-Cbl injections, carnitine supplementation and oral antibiotic therapy to decrease gut production of propionate. Special medical foods (formula) deficient in methionine, threonine, value, isoleucine, odd chain fatty acids and cholesterol. Liver transplant and liver/kidney transplant. Physical phenotype Most patients have no obvious dysmorphic features. Some patients, in whom there is known consanguinity, have had associated birth defects, congenital heart defects, hydronephrosis and facial dysmorphisms. Inheritance Autosomal recessive General population incidence N/A Ethnic differences None known	Symptoms	vomiting, dehydration which leads to profound metabolic acidosis, respiratory distress, hypotonia and death if not recognized. Complications of acute episodes can include metabolic stroke, extrapyramidal signs, dystonia and bilateral lucencies of globus pallidus. Survivors may have significant neurological damage. Renal failure may appear during childhood. Clinical spectrum is wide, ranging
Natural history with treatment About 60% of patients die within the first year of life and of those that survive, 40% are distinctly developmentally impaired. Age of onset of symptoms can help prognosticate – those with later onset tend to have a more benign course. Liver and liver/kidney transplant are one treatment option. However, liver transplants have significant preoperative risk and there is documentation of neurological problems after transplant despite improved biochemical values. Renal transplants have shown good response with drops in methylmalonic acid levels, normalization of the diet and absence of acute episodes of metabolic decompensation. However, the effect of any type of transplant is limited because the MMA enzyme is in all tissues and the transplants do not affect the levels made in the cerebrospinal fluid and brain. Treatment Protein restricted diet, OH-Cbl injections, carnitine supplementation and oral antibiotic therapy to decrease gut production of propionate. Special medical foods (fornula) deficient in methionine, threonine, valine, isoleucine, odd chain fatty acids and cholesterol. Liver transplant and liver/kidney transplant. Physical phenotype Most patients have no obvious dysmorphic features. Some patients, in whom there is known consanguinity, have had associated birth defects, congenital heart defects, hydronephrosis and facial dysmorphisms. Inheritance N/A General population incidence 1:48,000 Ethnic incidence N/A Propulation N/A Enzyme Function Catalyzes methylmalonyl-CoA to succinyl-CoA Missing Enzyme Methylmalonyl-CoA mutase <	Natural history without treatment	Variable depending on the enzyme defect and the patient. Some will die as a neonate, others will survive with deficits and a few others will remain
40% are distinctly developmentally impaired. Age of onset of symptoms can help prognosticate – those with later onset tend to have a more benign course. Liver and liver/kidney transplant are one treatment option. However, liver transplants have significant preoperative risk and there is documentation of neurological problems after transplant despite improved biochemical vulues. Renal transplants have shown good response with drops in methylmalonic acid levels, normalization of the diet and absence of acute episodes of metabolic decompensation. However, the effect of any type of transplant is limited because made in the cerebrospinal fluid and brain. Protein restricted diet, OH-Cbl injections, carnitine supplementation and oral antibiotic therapy to decrease gut production of propionate. Special medical foods (formula) deficient in methionine, threonine, valine, isoleucine, odd chain fatty acids and cholesterol. Liver transplant and liver/kidney transplant. Inheritance Autosomal recessive General population incidence 1/48,000 Ethnic differences None Population NiA Enzyme function Catalyzes methylmalonyl-CoA to succinyl-CoA Metabolite changes Increased methylmalonyl-CoA to succinyl-CoA Missing Enzyme Methylmalonyl-CoA mutase <t< th=""><th></th><th></th></t<>		
have shown good response with drops in methylmalonic acid levels, normalization of the diet and absence of acute episodes of metabolic decompensation. However, the effect of any type of transplant is limited because the MMA enzyme is in all tissues and the transplants do not affect the levels made in the cerebrospinal fluid and brain.TreatmentProtein restricted diet, OH-Cbl injections, carnitine supplementation and oral antibiotic therapy to decrease gut production of propionate. Special medical foods (formula) deficient in methionine, threonine, valine, isoleucine, odd chain fatty acids and cholesterol. Liver transplant and liver/kidney transplant.Physical phenotypeMost patients have no obvious dysmorphic features. Some patients, in whom there is known consanguinity, have had associated birth defects, congenital heart defects, hydronephrosis and facial dysmorphisms.Inheritance General population incidence Ethnic differencesN/AEthnic incidence Enzyme FunctionN/AEthnic incidence Enzyme FunctionLiver, kidneys, cerebrospinal fluid, brain Catalyzes methylmalonyl-CoA to succinyl-CoA MutasePrenatal testing Missing Enzyme Methylmalonyl-CoA mutaseIncreased methylmalonyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Link Genetests Link Support GroupMetwy coanews.org Save Babies through Societion Mww.savebabies.org Genetic Alliance	Natural history with treatment	40% are distinctly developmentally impaired. Age of onset of symptoms can help prognosticate – those with later onset tend to have a more benign course. Liver and liver/kidney transplant are one treatment option. However, liver transplants have significant preoperative risk and there is documentation of neurological
Treatmentmade in the cerebrospinal fluid and brain. Protein restricted diet, OH-Cbl injections, carnitine supplementation and oral antibiotic therapy to decrease gut production of propionate. Special medical foods (formula) deficient in methionine, threonine, valine, isoleucine, odd chain fatty acids and cholesterol. Liver transplant and liver/kidney transplant.Physical phenotypeMost patients have no obvious dysmorphic features. Some patients, in whom there is known consanguinity, have had associated birth defects, congenital heart defects, hydronephrosis and facial dysmorphisms.InheritanceAutosomal recessiveGeneral population incidence1:48,000Ethnic differencesNone knownPopulationN/AEtnzyme locationLiver, kidneys, cerebrospinal fluid, brainEnzyme FunctionCatalyzes methylmalonyl-CoA to succinyl-CoAMissing EnzymeMethylmalonyl-CoA mutaseMetabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on anniocytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkwww.genetests.org Save Babies through Screening Foundation www.aanews.org Save Babies through Screening Foundation www.aanews.org Save Babies through Screening Foundation www.aanews.org Genetic Alliance		have shown good response with drops in methylmalonic acid levels, normalization of the diet and absence of acute episodes of metabolic decompensation. However, the effect of any type of transplant is limited because
TreatmentProtein restricted dief, OH-Cbl injections, carnitine supplementation and oral antibiotic therapy to decrease gut production of propionate. Special medical foods (formula) deficient in methionine, threonine, valine, isoleucine, odd chain fatty acids and cholesterol. Liver transplant and liver/kidney transplant.Physical phenotypeMost patients have no obvious dysmorphic features. Some patients, in whom there is known consanguinity, have had associated birth defects, congenital heart defects, hydronephrosis and facial dysmorphisms.InheritanceAutosomal recessiveGeneral population incidence1:48,000Ethnic incidenceN/AEthnic incidenceN/AEthnic incidenceIver, kidneys, cerebrospinal fluid, brainEnzyme locationLiver, kidneys, cerebrospinal fluid, brainEnzyme FunctionCatalyzes methylmalonyl-CoA to succinyl-CoAMissing EnzymeMethylmalonyl-CoA mutaseMetabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on amniocytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkthtp://www.ncbi.nlm.nih.gov/omim/251000Www.gaenetss.org Support GroupOrganic Acidemia AssociationWww.oaanews.org 		
Physical phenotypeantibiotic therapy to decrease gut production of propionate. Special medical foods (formula) deficient in methionine, threonine, value, isoleucine, odd chain fatty acids and cholesterol. Liver transplant and liver/kidney transplant.Physical phenotypeMost patients have no obvious dysmorphic features. Some patients, in whom there is known consanguinity, have had associated birth defects, congenital heart defects, hydronephrosis and facial dysmorphisms.InheritanceAutosomal recessiveGeneral population incidence1:48,000Ethnic differencesNone knownPopulationN/AEthnic incidenceN/AEthnic incidenceN/AEnzyme locationLiver, kidneys, cerebrospinal fluid, brainEnzyme FunctionCatalyzes methylmalonyl-CoA to succinyl-CoAMissing EnzymeMethylmalonyl-CoA mutaseMetabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on amnicoytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkwww.genetests.orgSupport GroupOrganic Acidemia Association www.savebabies.orgSupport GroupOrganic Acidemia Association www.savebabies.org Genetic Alliance	Treatment	
Physical phenotype Most patients have no obvious dysmorphic features. Some patients, in whom there is known consanguinity, have had associated birth defects, congenital heart defects, hydronephrosis and facial dysmorphisms. Inheritance Autosomal recessive General population incidence 1:48,000 Ethnic differences None known Population N/A Ethnic incidence N/A Enzyme function Catalyzes methylmalonyl-CoA to succinyl-CoA Missing Enzyme Methylmalonyl-CoA mutase Metabolite changes Increased methylmalonic acid in blood and urine. Prenatal testing Possible via enzyme assay on amniocytes or CVS. MS/MS Profile Elevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine. OMIM Link www.genetests.org Support Group Organic Acidemia Association www.savebabies.org Ganetic Alliance		antibiotic therapy to decrease gut production of propionate. Special medical foods (formula) deficient in methionine, threonine, valine, isoleucine, odd chain fatty
InheritanceAutosomal recessiveGeneral population incidence1:48,000Ethnic differencesNone knownPopulationN/AEthnic incidenceN/AEnzyme locationLiver, kidneys, cerebrospinal fluid, brainEnzyme FunctionCatalyzes methylmalonyl-CoA to succinyl-CoAMissing EnzymeMethylmalonyl-CoA mutaseMetabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on amniocytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkhttp://www.ncbi.nlm.nih.gov/omim/251000Genetests Linkwww.genetests.orgSupport GroupOrganic Acidemia Associationwww.savebabies.orgSave Babies through Screening Foundationwww.savebabies.orgGenetic Alliance	Physical phenotype	there is known consanguinity, have had associated birth defects, congenital heart
Ethnic differencesNone knownPopulationN/AEthnic incidenceN/AEthnic incidenceN/AEnzyme locationLiver, kidneys, cerebrospinal fluid, brainEnzyme FunctionCatalyzes methylmalonyl-CoA to succinyl-CoAMissing EnzymeMethylmalonyl-CoA mutaseMetabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on amniocytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkhttp://www.ncbi.nlm.nih.gov/omim/251000Genetests Linkwww.genetests.orgSupport GroupOrganic Acidemia Associationwww.savebabies.orgSave Babies through Screening Foundationwww.savebabies.orgGenetic Alliance	Inheritance	
PopulationN/AEthnic incidenceN/AEnzyme locationLiver, kidneys, cerebrospinal fluid, brainEnzyme FunctionCatalyzes methylmalonyl-CoA to succinyl-CoAMissing EnzymeMethylmalonyl-CoA mutaseMetabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on amniocytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkwww.genetests.orgSupport GroupOrganic Acidemia Associationwww.oaanews.org Save Babies through Screening Foundationwww.savebabies.org Genetic Alliance	• •	
Ethnic incidenceN/AEnzyme locationLiver, kidneys, cerebrospinal fluid, brainEnzyme FunctionCatalyzes methylmalonyl-CoA to succinyl-CoAMissing EnzymeMethylmalonyl-CoA mutaseMetabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on amniocytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkhttp://www.ncbi.nlm.nih.gov/omim/251000Genetests Linkwww.genetests.orgSupport GroupOrganic Acidemia Associationwww.oaanews.org Save Babies through Screening Foundationwww.savebabies.org Genetic Alliance		
Enzyme locationLiver, kidneys, cerebrospinal fluid, brainEnzyme FunctionCatalyzes methylmalonyl-CoA to succinyl-CoAMissing EnzymeMethylmalonyl-CoA mutaseMetabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on amniocytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkhttp://www.ncbi.nlm.nih.gov/omim/251000Genetests Linkwww.genetests.orgSupport GroupOrganic Acidemia Associationwww.oaanews.org Save Babies through Screening Foundationwww.savebabies.org Genetic Alliance	•	
Enzyme FunctionCatalyzes methylmalonyl-CoA to succinyl-CoAMissing EnzymeMethylmalonyl-CoA mutaseMetabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on amniocytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkwww.genetests.orgSupport GroupOrganic Acidemia Associationwww.oaanews.orgSave Babies through Screening Foundationwww.savebabies.orgGenetic Alliance		
Missing EnzymeMethylmalonyl-CoA mutaseMetabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on amniocytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkhttp://www.ncbi.nlm.nih.gov/omim/251000Genetests Linkwww.genetests.orgSupport GroupOrganic Acidemia Associationwww.oaanews.orgSave Babies through Screening Foundationwww.savebabies.orgGenetic Alliance		
Metabolite changesIncreased methylmalonic acid in blood and urine.Prenatal testingPossible via enzyme assay on amniocytes or CVS.MS/MS ProfileElevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine.OMIM Linkhttp://www.ncbi.nlm.nih.gov/omim/251000Genetests Linkwww.genetests.orgSupport GroupOrganic Acidemia Associationwww.oaanews.orgSave Babies through Screening Foundationwww.savebabies.orgGenetic Alliance		
MS/MS Profile Elevated C3 propionyl carnitine, elevated C4 DC methylmalonyl carnitine. OMIM Link http://www.ncbi.nlm.nih.gov/omim/251000 Genetests Link www.genetests.org Support Group Organic Acidemia Association www.oaanews.org Save Babies through Screening Foundation www.savebabies.org Genetic Alliance		
OMIM Link http://www.ncbi.nlm.nih.gov/omim/251000 Genetests Link www.genetests.org Support Group Organic Acidemia Association www.oaanews.org Save Babies through Screening Foundation www.savebabies.org Genetic Alliance		
Genetests Link www.genetests.org Support Group Organic Acidemia Association www.oaanews.org Save Babies through Screening Foundation www.savebabies.org Genetic Alliance		
Support Group Organic Acidemia Association www.oaanews.org www.oaanews.org Save Babies through Screening Foundation www.savebabies.org Genetic Alliance Genetic Alliance		· ·
Save Babies through Screening Foundation www.savebabies.org Genetic Alliance		Organic Acidemia Association
www.savebabies.org Genetic Alliance		
Genetic Alliance		
		Genetic Alliance

Newborn Screening ACT Sheet [Elevated C3 Acylcarnitine] Propionic Acidemia and Methylmalonic Acidemia

Differential Diagnosis: Propionic acidemia (PA); Methylmalonic acidemias (MMA) including defects in B_{12} synthesis and transport; maternal severe B_{12} deficiency.

Condition Description: PA is caused by a defect in propionyl-CoA carboxylase which converts propionyl-CoA to methylmalonyl-CoA; MMA results from a defect in methylmalonyl-CoA mutase which converts methylmalonyl-CoA to succinyl-CoA or from lack of the required B_{12} cofactor for methylmalonyl-CoA mutase (cobalamin A, B, C, D, and F).

YOU SHOULD TAKE THE FOLLOWING ACTIONS IMMEDIATELY:

- Contact family to inform them of the newborn screening result and ascertain clinical status (poor feeding, vomiting, lethargy, tachypnea).
- Consult with pediatric metabolic specialist.
- Evaluate the newborn; check urine for ketones and, if elevated or infant is ill, initiate emergency treatment as
 indicated by metabolic specialist and transport immediately to tertiary center with metabolic specialist.
- Initiate timely confirmatory/diagnostic testing as recommended by specialist.
- Educate family about signs, symptoms and need for urgent treatment of hyperammonemia and metabolic acidosis (poor feeding, vomiting, lethargy, tachypnea).
- Report findings to newborn screening program.

Diagnostic Evaluation: Plasma acylcarnitine confirms the increased C3. Blood amino acid analysis may show increased glycine. Urine organic acid analysis will demonstrate increased metabolites characteristic of propionic acidemia or increased methylmalonic acid characteristic of methylmalonic acidemia. Plasma total homocysteine will be elevated in the cobalamin C, D and F deficiencies. Serum vitamin B_{12} may be elevated in the cobalamin disorders.

Clinical Considerations: Patients with PA and severe cases of MMA typically present in the neonate with metabolic ketoacidosis, dehydration, hyperammonemia, ketonuria, vomiting, hypoglycemia, and failure to thrive. Long-term complications are common, early treatment may be lifesaving and continued treatment may be beneficial.

Additional Information:

Emergency Protocols (New England Consortium of Metabolic Programs)

PA <u>MMA</u> Gene Reviews PA (Organic Acidemias Overview) <u>MMA</u> Genetics Home Reference PA <u>MMA</u> Referral (local, state, regional and national): Testing PA <u>MMA</u> <u>Clinical Services</u>

Disclaimer: This guideline is designed primarily as an educational resource for climicians to help them provide quality medical care It should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Adherence to this guideline does not necessarily ensure a successful medical outcome. In determining the propriety of any specific procedure or test, the elinician should apply his or her own professional judgment to the specific clinical irrumstances presented by the individual patient or specimen. Clinicians are encouraged to document the reasons for the use of a particular procedure or test, whether or not it is in conformance with this guideline. Clinicians also are advised to take notice of the date this guideline was adopted, and to consider other medical and scientific information that become available after that date.

© American College of Medical Genetics, 2010 (Funded in part through MCHB/HRSA/HHS grant #U22MC03957)



American College of Medical Genetics Medical Genetics: Translating Genes Into Health®